APA (7th ed.) Citation

J, Y., J, G., Z, P., TS, L., H, X., J, Y., . . . L, S. (2026). Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: A single-arm, multicenter phase 2 trial. British journal of cancer. https://doi.org/10.1038/s41416-026-03511-0

Chicago Style (17th ed.) Citation

J, Yuan, et al. "Efficacy and Safety of Infigratinib in Patients with Refractory Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Harboring FGFR2 Gene Amplification: A Single-arm, Multicenter Phase 2 Trial." British Journal of Cancer 2026. https://doi.org/10.1038/s41416-026-03511-0.

MLA (9th ed.) Citation

J, Yuan, et al. "Efficacy and Safety of Infigratinib in Patients with Refractory Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Harboring FGFR2 Gene Amplification: A Single-arm, Multicenter Phase 2 Trial." British Journal of Cancer, 2026, https://doi.org/10.1038/s41416-026-03511-0.